BCL2L1 and neoplasm: Importantly, DBP can identify these dynamic anti-apoptotic protein dependencies using synthetic BH3 peptides that mimic sensitizer BCL-2 family proteins (an increase in priming using the BAD BH3 peptide would indicate BCL-2/BCL-xL tumor dependence; the HRK BH3 peptide, BCL-xL dependence; and the MS1 BH3 peptide, MCL-1 dependence) [12, 22, 27, 36, 37].